CARLSBAD, Calif.--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has granted premarket approval to Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) to ...
The FDA approved the Oncomine Dx Target Test for identifying HER2-mutant NSCLC patients eligible for Hernexeos, an oral tyrosine kinase inhibitor. Hernexeos offers a new treatment option for ...
A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...
The US Food and Drug Administration (FDA) has granted approval for Thermo Fisher Scientific's Oncomine Dx Target Test as a treatment for non-small cell lung cancer (NSCLC). The test serves as a ...
The National Comprehensive Cancer Network’s newly updated non-small cell lung cancer guideline adds sevabertinib as a treatment option for some patients with advanced disease, makes datopotamab ...
Real world data for venous thromboembolisms (VTEs) in patients with active cancer: Thromboprophylaxis pooled analysis from GMaT and ACT4CAT studies.
Next-generation sequencing (NGS) is a crucial component of evaluation of patients with newly diagnosed metastatic non–small-cell lung cancer (NSCLC) to determine appropriate first-line treatment. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results